Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in High-Risk Biochemically Relapsed Prostate Cancer
NCT03009981Phase 3Completed
- Sponsor
- Alliance Foundation Trials
- Start
- Mar 2017
- Primary completion
- Jun 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide in prostate cancer (PCa) (3 arms), sponsored by Alliance Foundation Trials. Primary endpoint: PSA progression-free survival in the intent-to-treat population at 36 months. Started Mar 2017; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03009981.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03009981.